Ponni Subbiah

Chief Medical Officer & Senior Vice President at ACADIA Pharmaceuticals, Inc.

Ponni Subbiah

Ponni Subbiah

Chief Medical Officer & Senior Vice President at ACADIA Pharmaceuticals, Inc.

Overview
RelSci Relationships

461

Number of Boards

2

Relationships
RelSci Relationships are individuals Ponni Subbiah likely has professional access to. A relationship does not necessarily indicate a personal connection.

Director at Assn. for Accred. of Human Research Protection Programs, Inc.

Relationship likelihood: Strong

Director at Assn. for Accred. of Human Research Protection Programs, Inc.

Relationship likelihood: Strong

Director at Assn. for Accred. of Human Research Protection Programs, Inc.

Relationship likelihood: Strong

President at The Pfizer Foundation, Inc.

Relationship likelihood: Strong

Vice Chair at Assn. for Accred. of Human Research Protection Programs, Inc.

Relationship likelihood: Strong

Chief Executive Officer at ACADIA Pharmaceuticals, Inc.

Relationship likelihood: Strong

Chief Communications Officer at ACADIA Pharmaceuticals, Inc.

Relationship likelihood: Strong

Dean Emeritus at California Western School of Law

Relationship likelihood: Strong

Chief Scientific Officer at Novartis Pharmaceuticals Corp.

Relationship likelihood: Strong

Former President & Chief Operating Officer at Advarra, Inc.

Relationship likelihood: Strong

Paths to Ponni Subbiah
Potential Connections via
Relationship Science
You
Ponni Subbiah
Chief Medical Officer & Senior Vice President at ACADIA Pharmaceuticals, Inc.
Education

Johns Hopkins Bloomberg School of Public Health provides research, education, and practice to find solutions for health problems. Since its founding in 1916, the Bloomberg School has advanced research, education, and practice to create solutions to public health problems around the world. Faculty, staff, and students have helped eradicate smallpox, made water safe to drink, improved child survival, reduced the spread of HIV, and uncovered the dangers of tobacco smoke. Researchers and scientists are now discovering ways to eliminate malaria, increase healthy behavior, reduce the toll of chronic disease, improve the health of mothers and infants, and change the biology of aging. Every day, the Bloomberg School works to keep millions around the world safe from illness and injury by pioneering new research, deploying knowledge in the field, and educating tomorrow's public health leaders.

Madras Medical College

Career History
Chief Medical Officer & Senior Vice President
2019 - Current

ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company. It focuses on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firm's products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Chief Medical Officer
2016 - 2019

Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, Subutex Tablet, and Sublocade Injection. The company was founded on September 26, 2014 and is headquartered in Slough, the United Kingdom.

Director, Drug Development
Prior

Program for Appropriate Technology in Health provides social healthcare services. Its platform includes vaccines, drugs, diagnostics and devices. The firm offers treatment for malaria, pneumonia and diarrheal. The company was founded in 1977 and is headquartered in Seattle, WA.

Boards & Committees
Vice President
Tenure Unconfirmed

Over the last five years, the Pfizer Foundation and Pfizer Worldwide Philanthropy department has developed platform focused on investing the full range of the company's resources — people, skills, expertise and funding — to broaden access to medicines and strengthen healthcare delivery for underserved people around the world. The new philanthropy platform, Pfizer Investments in Health, offers a more coordinated approach to contribute to society beyond medicines, centered around developing stronger relationships with their partners (grantees, field experts, etc.) and including cash grants, capacity building/technical assistance, product, skilled volunteers and stronger networking. This has resulted in mutual benefits for Pfizer and for its philanthropic partners. Introduction The Pfizer Foundation, the philanthropic arm of the world-leading pharmaceutical company, Pfizer Inc, is committed to addressing global health needs through community programs that also leverage its corporate resources and connections. Pfizer had successfully implemented international and smaller scale domestic HIV/AIDS programs, but recognized the need for greater national attention. In 2002, the Pfizer Foundation developed the Southern HIV/AIDS Prevention Initiative (SHAPI) in reaction to the growing HIV/AIDS epidemic in the southern United States. HIV/AIDS rates were still alarmingly high and growing, especially in the U.S. South. SHAPI, a three-year program from 2003 to 2006, provided more than $3 million in program investments and $3 million in capacity-building opportunities. To further develop the program and assist in its strategic planning and implementation the Foundation engaged TCC Group in 2002. Developing Focus and Goals In response to TCC Group's research and facilitated discussions with stakeholders, the Pfizer Foundation focused SHAPI on prevention programs in small to mid-size AIDS Service Organizations (ASOs), particularly those working with minorities and women. With TCC's help, the Foundation developed a clear set of goals for SHAPI. The core strategy focused on building relationships and supporting a targeted number of organizations, and included investments focused on direct services in local prevention and education programs and additional investments designed to create longer lasting impact through organizational capacity building and regional networking opportunities. Together, TCC and the Pfizer Foundation selected 23 grantees and 39 additional finalists. Grantees were provided annual grants of up to $50,000 for prevention programs, and all grantees and finalists were provided with opportunities to improve organizational effectiveness and be a part of the SHAPI network. TCC managed the overall initiative and worked closely with grantees to achieve the SHAPI goals of capacity building and networking. Opportunities Beyond the Grants In order to offer grantees tailored capacity building opportunities, TCC Group developed a new, comprehensive assessment tool for nonprofit organizations that was based on best practices in the field and tested by leading ASOs (now further developed, available on-line and called the Core Capacity Assessment Tool (CCAT)). Using the CCAT, TCC identified target areas for capacity building in each participating organization as well as cross-cutting needs for clusters of organizations. Each SHAPI grantee was offered annual customized capacity building recommendations and funding support (which often was nearly equal to their program grant) as well as general opportunities, such as board development, peer mentoring, software and technology training, financial management, and evaluation technical assistance. In addition, TCC worked with the Foundation to provide networking opportunities to the SHAPI grantees and finalists, such as training sessions, teleconferences, and peer exchange. In particular, the Pfizer Foundation sponsored its SHAPI partners to attend the annual United States Conference on AIDS and hosted its own annual HIV/AIDS prevention conferences focused on HIV/AIDS prevention and capacity building needs identified throughout the year. During these networking opportunities, the Pfizer Foundation invited and introduced Pfizer Inc's HIV Community Liaisons (HCLs) to SHAPI partners to be able to foster more localized relationships with Pfizer Inc and to provide access to Pfizer Inc's local resources, such as training materials, mini-grants/sponsorships and volunteers. Through these networking opportunities, grantees and finalists shared ideas, information, and inspiration. "Long after Pfizer's funding relationship with [us] has concluded, the skills and expertise culled from these capacity-building efforts will continue to make [us] a trusted and well-respected organization." – NC Grantee

Non-Profit Donations & Grants

Learn how non-profit organizations benefit from RelSci
$500 - $999
2011

AMREF is a non-governmental health development organization based in Africa. They manage a range of medical and public health programs focused on the vulnerable populations – women and children – and critical health issues facing the African continent such as HIV/AIDS and tuberculosis, Malaria,cClean water and sanitation, family health, training health workers, clinical and surgical outreach.

Other Affiliations
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Ponni Subbiah. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Ponni Subbiah's profile does not indicate a business or promotional relationship of any kind between RelSci and Ponni Subbiah.